1044591-98-1

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-methoxycarbonyl-(R)-5-methylpiperidine is utilized as a key intermediate in the synthesis of various drugs, particularly those aimed at targeting the central nervous system. Its unique structure and chirality allow for the development of novel therapeutic agents with potential applications in treating neurological disorders and conditions.
Used as a Chiral Building Block in Organic Synthesis:
Due to its chiral nature, (R)-3-methoxycarbonyl-(R)-5-methylpiperidine serves as an essential building block in the creation of more complex organic molecules. (R)-3-methoxycarbonyl-(R)-5-methylpiperidine can be further modified and functionalized to produce a wide range of chemical products with specific applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Further Research and Development:
The potential applications of (R)-3-methoxycarbonyl-(R)-5-methylpiperidine are not limited to the current uses mentioned above. Ongoing research and development efforts may lead to the discovery of new pharmaceuticals and chemical products that leverage the unique properties of (R)-3-methoxycarbonyl-(R)-5-methylpiperidine. As our understanding of its structure and reactivity grows, so too will the range of applications for (R)-3-methoxycarbonyl-(R)-5-methylpiperidine in various industries.

Upstream product

• 29681-45-6 5-methylnicotinic acid methyl ester 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 

Downstream Products

• 1269757-29-0 (3R,5S)-/(3S,5R)-1-(benzyloxycarbonyl)-5-methylpiperidine-3-carboxylic acid 
• 1269757-29-0 (3R,5R)-/(3S,5S)-1-(benzyloxycarbonyl)-5-methylpiperidine-3-carboxylic acid 
• 1365887-45-1 1-(tert-butoxycarbonyl)-5-methylpiperidine-3-carboxylic acid 
• 1365887-44-0 1-(tert-butyl) 3-methyl 5-methylpiperidine-1,3-dicarboxylate 
• 1366053-19-1 1-(2-fluorobenzyl)-5-methylpiperidine-3-carboxylic acid 
• 1366052-54-1 N-(1-(2-fluorobenzyl)-5-methylpiperidin-3-yl)-3-(pyridin-4-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxamide 

Relevant academic research and scientific papers

1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability

The first highly potent and selective PDE8 inhibitors are disclosed. The initial tetrahydroisoquinoline hit was transformed into a nipecotic amide series in order to address a reactive metabolite issue. Reduction of lipophilicity to address metabolic liab

FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS

Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE

Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor